News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

UCB, Inc. (UCBJF.PK) Launches Neupro® in the U.S. to Treat Parkinson's Disease and Restless Legs Syndrome


7/16/2012 9:43:15 AM

BRUSSELS & ATLANTA--(BUSINESS WIRE)--UCB announced today that Neupro® (Rotigotine Transdermal System) is now available in U.S. pharmacies. Neupro® was approved by the U.S. Food and Drug Administration in April to treat the signs and symptoms of early and advanced stage idiopathic Parkinson’s disease and moderate-to-severe primary Restless Legs Syndrome.

Read at BioSpace.com

comments powered by Disqus
UCB, Inc.
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES